Bibi, D.; Steiner, L.; Krtalic, I.; Juretic, M.; Cetina-Cizmek, B.; Komlosi, A.; Loupe, P.; Ferderber, K.; Hallak, H.
Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics. Pharmaceutics 2026, 18, 601.
https://doi.org/10.3390/pharmaceutics18050601
AMA Style
Bibi D, Steiner L, Krtalic I, Juretic M, Cetina-Cizmek B, Komlosi A, Loupe P, Ferderber K, Hallak H.
Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics. Pharmaceutics. 2026; 18(5):601.
https://doi.org/10.3390/pharmaceutics18050601
Chicago/Turabian Style
Bibi, David, Lilach Steiner, Iva Krtalic, Marina Juretic, Biserka Cetina-Cizmek, Andrea Komlosi, Pippa Loupe, Kristina Ferderber, and Hussein Hallak.
2026. "Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics" Pharmaceutics 18, no. 5: 601.
https://doi.org/10.3390/pharmaceutics18050601
APA Style
Bibi, D., Steiner, L., Krtalic, I., Juretic, M., Cetina-Cizmek, B., Komlosi, A., Loupe, P., Ferderber, K., & Hallak, H.
(2026). Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics. Pharmaceutics, 18(5), 601.
https://doi.org/10.3390/pharmaceutics18050601
